pharmaceutical daily

March 5, 2026 0

The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon

By Dino Mustafić

The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon

March 4, 2026 Off

Faron Pharmaceuticals goes back to shareholders – with weeks of cash left and potentially historic blood cancer data

By Dino Mustafić

An 80 million share rights offering authorized in Turku signals a company racing against its own runway

March 3, 2026 Off

UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?

By Dino Mustafić

BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI

March 3, 2026 Off

Germany Goes to Beijing: What the Merz-Xi summit means for pharma and life sciences

By Dino Mustafić

CEO of Leica Microsystems, a Danaher company — one of the few life sciences representatives in a room otherwise dominated by automotive and industrial giants.

February 27, 2026 Off

AI and job cuts: What the block layoffs signal for pharma and beyond

By Dino Mustafić

In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to artificial intelligence (AI) and automation — not just general cost-cutting. The biggest recent example comes from fintech firm Block Inc., which announced plans to cut over 4,000 jobs — roughly 40 % of its workforce — as AI tools reshape how it builds and runs its business, according to multiple news reports. What about pharma?

February 26, 2026 Off

Three days, three signals: What some of the recent pharma deals and earnings reveal about 2026 strategy

By Dino Mustafić

A wave of oncology M&A, targeted mid-cap acquisitions, and cautious earnings guidance suggests pharma is entering a new capital discipline cycle. Here’s what investors should watch.

February 26, 2026 Off

Hikma reports revenue rowth, but stock falls on cautious forecast, amid leadership changes

By Dino Mustafić

UK-based Hikma Pharmaceuticals posted higher annual revenue and strong performance in its injectables segment, but investors reacted negatively to its outlook, sending shares to a three-year low.

February 26, 2026 Off

GSK purchases 35Pharma for $950M to expand into pulmonary hypertension

By Dino Mustafić

GlaxoSmithKline has entered into an agreement to acquire Canadian clinical-stage biotech 35Pharma Inc. for $950 million in cash, expanding its respiratory and cardiovascular pipeline, according to regulatory filings and the company’s announcement.

February 26, 2026 Off

Gilead Sciences buys Arcellx for $7.8B, doubling down on CAR-T oncology strategy

By Dino Mustafić

Gilead Sciences has agreed to acquire cancer therapy developer Arcellx Inc. in a transaction valued at up to $7.8 billion, deepening its footprint in cell therapy for blood cancers

February 26, 2026 Off

The ADC arms race: payload power vs targeting precision

By Dino Mustafić

Over the past decade, antibody-drug conjugates (ADCs) have emerged as a high-impact class of cancer therapies, blending the selectivity of antibodies with the potency of cytotoxic payloads. But as the modality matures, a structural tension is becoming clear: should innovation focus on chemical escalation of payloads and linkers, or on biological precision of target engagement?

pharmaceutical daily

The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon

Faron Pharmaceuticals goes back to shareholders – with weeks of cash left and potentially historic blood cancer data

UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?

Germany Goes to Beijing: What the Merz-Xi summit means for pharma and life sciences

AI and job cuts: What the block layoffs signal for pharma and beyond

Europe

The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon

UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?

Germany Goes to Beijing: What the Merz-Xi summit means for pharma and life sciences

USA

GSK purchases 35Pharma for $950M to expand into pulmonary hypertension

BMS, Bain Capital create new company to focus on therapies for autoimmune diseases

Moderna reports full-year revenues of $3.2 billion, down from $6.8 in 2023 as Covid-19 vax sales drops

My Pharmaceutical

AI and job cuts: What the block layoffs signal for pharma and beyond

The ADC arms race: payload power vs targeting precision

Bispecific ADCs: are dual-target ‘AND-Gate’ designs the future of tumour selectivity?

The quiet revolution in heart disease: How siRNA is becoming cardiology’s most powerful new weapon

Faron Pharmaceuticals goes back to shareholders – with weeks of cash left and potentially historic blood cancer data

UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?

Germany Goes to Beijing: What the Merz-Xi summit means for pharma and life sciences

AI and job cuts: What the block layoffs signal for pharma and beyond

Three days, three signals: What some of the recent pharma deals and earnings reveal about 2026 strategy

Hikma reports revenue rowth, but stock falls on cautious forecast, amid leadership changes

GSK purchases 35Pharma for $950M to expand into pulmonary hypertension

Gilead Sciences buys Arcellx for $7.8B, doubling down on CAR-T oncology strategy

The ADC arms race: payload power vs targeting precision